Well, you win some and you lose some. As expected (by the market – not by my guru), the FDA approved Dendreon’s application. Provenge – which is projected to cost $100,000 a year and said to add 4 months to a late-stage prostate cancer patient’s life – can now, at last be marketed.
Dendreon stock, which had climbed from $2.50 to $40 in anticipation of this, ended the day at $51, up around 11. All my precious little contrarian puts – and yours, if you took this bet – went effectively to zero.
Guru writes: “Politics trumped science and has now saddled the healthcare system with an annual $10 billion bill for a placebo. It’s the first time in my career that the FDA caved to popular demand.”
I hope he’s wrong. (He does, too.) If the drug really works, and really extends life, then the only question is how much of it we can afford.
But guru believes further studies will eventually show Provenge to have no effect.
Meanwhile, I’m not going to fling myself from a parapet – not least because the DCTH he recommended a few months ago has now nearly tripled.
But I am going to take the rest of the day off. I just wanted to be sure to tell you the coin-flip turned up heads, and commiserate with any of you joined me in betting against it.
Quote of the Day
Spending tens of thousands of dollars on a person's last few months of life is compassionate, but spending tens of thousands of dollars to improve a person's first few years of life is investment.~.
Request email delivery
- Nov 19:
The Prices Are Just Too Damned High — And Here’s Why
- Nov 18:
Mugged by a 90-Year-Old?
- Nov 16:
Arms For Dirt
- Nov 15:
Plant A Tree — How Scientists Got It So Wrong
- Nov 14:
But Does It Rise . . . Part 2
- Nov 13:
But Does It Rise To The Level?
- Nov 12:
- Nov 10:
Chickens Are Smarter Than They Look
- Nov 8:
Music For The Rest Of Us
- Nov 7:
Music For Elephants
- Nov 19: